Financial Performance - The company's revenue for Q3 2022 was ¥274,460,009.01, representing a 30.59% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥19,893,333.71, an increase of 8.11% year-on-year, but a significant decrease of 77.95% year-to-date[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,978,010.55, up 3.43% for the quarter, but down 83.51% year-to-date[5]. - The company's basic earnings per share for Q3 2022 was ¥0.12, a 9.09% increase from the previous quarter, but a decrease of 77.78% year-to-date[5]. - The net profit for Q3 2022 was CNY 26,405,977.46, a decrease from CNY 119,728,893.47 in the same period last year, representing a decline of approximately 78%[20]. - Operating profit for Q3 2022 was CNY 30,433,524.16, down from CNY 138,122,968.60 year-over-year, indicating a decrease of about 78%[20]. - The company reported a decrease in sales revenue from CNY 771,279,447.62 in the previous year to CNY 666,798,759.38 in Q3 2022, a decline of approximately 13.5%[22]. - The basic and diluted earnings per share for Q3 2022 were both CNY 0.16, down from CNY 0.72 in the same period last year, a decrease of about 77.8%[20]. - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[19]. - The company's total profit for Q3 2022 was CNY 28,460,408.21, significantly lower than CNY 137,767,113.63 in the same quarter of the previous year, indicating a decline of about 79%[20]. Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was ¥73,333,293.95, down 38.68% compared to the previous year[5]. - The net cash flow from operating activities for the first nine months of 2022 was ¥73,333,293.95, a decrease of 38.68% compared to ¥119,590,909.85 in the same period of 2021, primarily due to an increase in accounts receivable[9]. - The net cash flow from investing activities was -¥800,628,862.76, a significant decline of 1,488.89% from -¥50,389,141.10 in the previous year, mainly due to increased purchases of financial products[9]. - The net cash flow from financing activities decreased to -¥55,047,377.41, down 1,089.15% from ¥5,565,130.91, primarily due to increased cash repayments of loans[9]. - The net increase in cash and cash equivalents was -¥782,282,322.99, a decrease of 1,146.48% compared to an increase of ¥74,753,982.87 in the previous year, mainly due to net outflows from investing activities[9]. - Cash flow from operating activities for Q3 2022 was CNY 73,333,293.95, compared to CNY 119,590,909.85 in the previous year, reflecting a decline of approximately 39%[22]. - Total cash flow from investing activities was negative CNY 800,628,862.76 in Q3 2022, worsening from negative CNY 50,389,141.10 in the same period last year[22]. - Cash flow from financing activities resulted in a net outflow of CNY 55,047,377.41 in Q3 2022, compared to a net inflow of CNY 5,565,130.91 in the previous year[23]. - The total cash and cash equivalents at the end of Q3 2022 stood at CNY 183,858,359.05, down from CNY 360,261,233.85 at the end of Q3 2021[23]. - The company's total assets at the end of Q3 2022 were ¥2,770,809,269.95, a 1.06% increase from the end of the previous year[5]. - The company's total assets as of September 30, 2022, amounted to CNY 2,770,809,269.95, slightly up from CNY 2,741,662,030.01 at the beginning of the year[18]. - Cash and cash equivalents were CNY 323,047,579.17, down from CNY 1,068,233,710.99 at the beginning of the year, indicating a significant liquidity reduction[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,259, with no preferred shareholders having restored voting rights[11]. - Wuhan Tongsheng Investment Co., Ltd. held 49.86% of the shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[11]. - The company repurchased a total of 1,522,850 shares, representing 0.92% of the total share capital, with a total transaction amount of ¥30,947,790.28[13]. Expenses and Liabilities - Management expenses increased by 34.81% year-to-date, primarily due to higher salaries and depreciation[8]. - The company experienced a 306.86% increase in financial expenses year-to-date, attributed to the capitalization of convertible bond interest[8]. - Current liabilities totaled CNY 593,053,059.52, an increase of 17.83% from CNY 503,268,977.63 in the previous period[17]. - The total non-current liabilities were CNY 618,392,189.95, showing a slight decrease from CNY 619,539,266.83 in the previous period[17]. - The total equity attributable to shareholders decreased to CNY 1,559,364,020.48 from CNY 1,618,853,785.55, reflecting a decline of 3.6%[18]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[19]. - The company has not disclosed any new product or technology developments, market expansions, or mergers and acquisitions in the current report[12].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥397 million, a decrease of 25.89% compared to ¥535 million in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥6.51 million, down 93.57% from ¥101 million in the previous year[22]. - The net cash flow from operating activities decreased by 58.34% to approximately ¥25.81 million, compared to ¥61.97 million in the same period last year[23]. - The basic earnings per share for the first half of 2022 was ¥0.04, a decline of 93.44% from ¥0.61 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.38 million, a decrease of 98.55% from ¥94.95 million in the same period last year[23]. - The company achieved operating revenue of ¥397,018,762.74, a decrease of 25.89% compared to the previous year[44]. - The net profit attributable to shareholders was ¥6,512,643.75, down 93.57% year-on-year[44]. - The decline in revenue was primarily due to the continued downturn in the downstream breeding industry, which affected the scale of breeding and the usage of veterinary drugs[44]. - Operating profit for the first half of 2022 was CNY 10,365,515.08, down from CNY 118,198,274.68 in the first half of 2021[196]. - Net profit for the first half of 2022 was CNY 6,512,643.75, a significant decline from CNY 101,328,223.25 in the first half of 2021, representing a decrease of approximately 94%[197]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.68 billion, a decrease of 2.19% from ¥2.74 billion at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 3.29% to approximately ¥1.57 billion, compared to ¥1.62 billion at the end of the previous year[23]. - Total liabilities amounted to 1,116.09 million, a slight decrease from 1,122.81 million at the end of the previous year[192]. - The company's asset-liability ratio at the end of the reporting period was 41.62%, an increase of 0.67% compared to the end of the previous year[184]. - Total assets as of June 30, 2022, amounted to CNY 2,375,493,122.08, slightly down from CNY 2,392,531,740.25 at the beginning of the year[195]. - Total liabilities increased to CNY 857,517,112.54 as of June 30, 2022, compared to CNY 827,779,576.09 at the start of the year[195]. Research and Development - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[39]. - Research and development expenses increased by 16.79% to CNY 17,680,760.33, reflecting the company's commitment to innovation[58]. - Research and development expenses for the first half of 2022 were CNY 17,680,760.33, an increase from CNY 15,138,572.29 in the same period of 2021[196]. Product Development and Market Strategy - The company has obtained 142 veterinary drug approval numbers as of June 2022, focusing on pig medications while expanding into poultry, aquaculture, and pet pharmaceuticals[32]. - Revenue from poultry products increased by 3.29% and from aquaculture products by 1.96%, indicating a diversification strategy to mitigate cyclical fluctuations in the pig farming industry[33]. - The company successfully launched the fourth-generation animal-specific antibiotic, Tylosin Injection, and improved the fermentation process of Tylvalosin, increasing efficacy by 4.5% and average yield by 6.7% compared to 2021[33]. - The company has launched 11 pet health products and 2 pet medications, expanding its product offerings in the pet care market[33]. - The company aims to enhance its customer coverage and penetration in the pig medicine sector while expanding into other areas such as poultry and aquaculture to mitigate risks from the pig cycle[92]. Financial Management and Investments - The company reported a significant increase in financial expenses by 173.44% to CNY 2,829,847.73, mainly due to the accrual of convertible bond interest[58]. - The total amount of funds raised by the company is RMB 154,001.15 million, with RMB 42,542.20 million invested during the reporting period[72]. - The company made a significant investment of CNY 10,000,000.00 in Hubei Animal Health Technology Development Co., Ltd., acquiring a 100% stake[68]. - The company has committed to various projects with a total investment of RMB 129,000 million, of which RMB 127,929.90 million has been invested as of the reporting period[80]. Corporate Governance and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[123]. - The company has not engaged in any major related party transactions during the reporting period, ensuring transparency and compliance[126]. - The company has not experienced any non-operating fund occupation by major shareholders or related parties during the reporting period, reflecting financial integrity[118]. - The company has adhered to all relevant environmental regulations and is actively working towards sustainable development[114]. Shareholder Information - The major shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.86% of the shares, totaling 82,800,000 shares, which are subject to a 36-month lock-up period[163]. - The total number of shareholders at the end of the reporting period was not specified, but significant changes in shareholding were noted among major shareholders[163]. - The company’s shareholding structure showed a slight decrease in the proportion of restricted shares from 50.10% to 50.04%[149]. Future Outlook - The company’s future outlook includes maintaining its current credit rating and managing its restricted shares effectively[160]. - The company plans to strengthen project management to ensure timely production of fundraising projects and actively expand the market to increase product market share[99].

Financial Performance - The company's revenue for Q1 2022 was ¥205,665,754.61, a decrease of 34.40% compared to ¥313,499,906.84 in the same period last year[5] - Net profit attributable to shareholders was ¥2,023,854.94, down 96.81% from ¥63,457,333.99 year-on-year[5] - Basic earnings per share dropped to ¥0.01, a decline of 97.37% from ¥0.38 in the previous year[6] - Total operating revenue for Q1 2022 was CNY 205,665,754.61, a decrease of 34.4% compared to CNY 313,499,906.84 in Q1 2021[28] - Gross profit for Q1 2022 was CNY 4,179,499.36, significantly lower than CNY 73,631,806.44 in Q1 2021, indicating a decline of 94.3%[30] - Net profit for Q1 2022 was CNY 2,023,854.94, a decrease of 96.8% compared to CNY 63,457,333.99 in Q1 2021[30] - Basic earnings per share for Q1 2022 were CNY 0.01, down from CNY 0.38 in Q1 2021[31] Cash Flow - The net cash flow from operating activities was -¥16,025,127.81, an improvement of 20.12% compared to -¥20,061,570.80 in the same period last year[6] - Total cash inflow from operating activities was 223,182,661.77, down from 305,652,169.46 in the previous period, indicating a decrease of approximately 27%[34] - Cash outflow from operating activities totaled 239,207,789.58, compared to 325,713,740.26 in the previous period, reflecting a decrease of about 26.5%[34] - The net cash flow from investing activities was -¥376,449,232.15, a decline of 347.08% compared to ¥152,360,259.27 in the previous year[15] - Cash inflow from investing activities was 30,353,258.20, down from 411,485,219.59 in the previous period, representing a decrease of approximately 92.6%[35] - Cash outflow from investing activities increased to 406,802,490.35, compared to 259,124,960.32 in the previous period, marking an increase of about 56.9%[35] - Cash inflow from financing activities was 70,000,000.00, up from 20,000,000.00 in the previous period, indicating a growth of 250%[35] - The net cash flow from financing activities was 1,375,366.95, compared to -18,216,687.38 in the previous period, showing a turnaround[35] - The ending cash and cash equivalents balance was 575,070,614.85, compared to 399,596,815.86 in the previous period, reflecting an increase of approximately 44%[35] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,701,491,465.45, a decrease of 1.47% from ¥2,741,662,030.01 at the end of the previous year[6] - Total liabilities for Q1 2022 were CNY 1,135,079,667.38, compared to CNY 1,122,808,244.46 in Q1 2021, showing a slight increase of 1.1%[27] - Current assets decreased to CNY 1,431,758,454.96 from CNY 1,598,881,606.08, a decline of 10.5% year-over-year[26] - Non-current assets increased to CNY 1,269,733,010.49 from CNY 1,142,780,423.93, reflecting an increase of 11.1%[27] - The company’s total liabilities increased by 40.00% in short-term borrowings, amounting to ¥140,000,000.00, due to increased borrowing during the reporting period[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,594[17] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.80% of shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[18] - The top ten shareholders include several investment firms, indicating a diverse ownership structure[19] - The company reported cash dividends of RMB 3.31 per 10 shares, totaling RMB 55,028,262.43 distributed to shareholders[22] Research and Development - Research and development expenses increased by 64.91% to ¥9,754,406.16, reflecting the company's commitment to enhancing R&D efforts[14] - The company reported a significant increase in research and development expenses, which rose to CNY 9,754,406.16 from CNY 5,914,988.69, marking a growth of 64.1%[29] Performance Goals - The company adjusted its performance assessment indicators for the 2021 restricted stock incentive plan, requiring a net profit growth rate of no less than 30% for 2021[20] - The company plans to achieve a revenue or net profit growth of no less than 65% for 2022, based on 2020 figures[20] Other Information - The company experienced a 1124.09% increase in non-operating expenses, totaling ¥2,010,149.96, primarily due to increased donations for university collaborations[14] - The company has initiated the repurchase and cancellation of 195,200 shares from the 2021 incentive plan[21] - As of March 31, 2022, cash and cash equivalents decreased to RMB 682,339,687.30 from RMB 1,068,233,710.99 at the beginning of the year, a decline of approximately 36.2%[24] - Accounts receivable increased to RMB 249,964,032.82 from RMB 231,856,552.45, reflecting a growth of about 7.8%[24] - Inventory decreased to RMB 201,968,517.77 from RMB 231,550,585.15, a reduction of approximately 12.7%[24] - The company’s first quarter report was not audited[36]

Financial Performance - The company's sales revenue from group farming customers reached RMB 609.30 million, an increase of 41.03% compared to the previous year[7]. - The company's operating revenue for 2021 was ¥996,216,817.61, representing a 28.14% increase from ¥777,458,548.09 in 2020[27]. - The net profit attributable to shareholders decreased by 11.52% to ¥132,865,534.22 in 2021, down from ¥150,156,108.11 in 2020[27]. - The company achieved a historic breakthrough in sales performance with a revenue of 996.22 million yuan, representing a year-on-year growth of 28.14%[58]. - The total revenue for 2021 was CNY 937,754,212.27, with a year-on-year increase of 31.67%[70]. - The revenue from veterinary chemical preparations was CNY 845,575,303.03, accounting for 84.88% of total revenue, with a growth of 34.64% compared to the previous year[70]. - The revenue from exports surged by 240.07% to CNY 12,865,408.39, indicating strong international demand[70]. - The revenue from South China region grew by 90.87% to CNY 211,245,158.45, highlighting market expansion efforts[70]. Cash Flow and Assets - The net cash flow from operating activities surged by 222.07% to ¥155,718,489.99, compared to ¥48,349,261.08 in the previous year[27]. - The company's cash and cash equivalents at the end of the period reached 966.14 million yuan, up 238.39% year-on-year, primarily due to funds raised from convertible bonds and operational accumulation[64]. - The company's total assets at the end of 2021 reached ¥2,741,662,030.01, a 56.47% increase from ¥1,752,225,832.51 at the end of 2020[27]. - The company's cash dividend distributed to shareholders is RMB 55,028,262.44, which accounts for 100% of the total profit distribution[172]. Research and Development - The company’s R&D expenses rose by 65.20% year-on-year to 46.89 million yuan, reflecting a strengthened focus on technological innovation[64]. - The company has established four major R&D platforms, including the Hubei Animal Health Engineering Technology Research Center, to accelerate new drug development and commercialization[119]. - The company has made significant progress in developing new veterinary drugs, with one product already on the market and another in the final stages of clinical trials[80]. - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[48]. Market Position and Strategy - The company has established stable partnerships with well-known domestic agricultural enterprises, enhancing its market presence and brand recognition[41]. - The company holds 143 veterinary drug approval numbers, focusing on a diverse range of products including antimicrobial and antiparasitic drugs for pigs, poultry, aquaculture, and pets[43]. - The marketing strategy combines direct sales to large-scale breeding groups and a dealer model for small and medium-sized farms, ensuring comprehensive market coverage[50]. - The company is focusing on vertical integration in the upstream raw material industry and horizontal expansion in various animal health sectors[118]. Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, enhancing its operational transparency[129]. - The company has established a dedicated investor relations section on its official website, facilitating communication with investors[129]. - The company’s board consists of 5 members, including 2 independent directors, ensuring compliance with governance standards[126]. - The company has implemented a network voting platform for shareholders to express their opinions during meetings, promoting shareholder engagement[125]. Employee and Management - The total number of employees at the end of the reporting period is 828, with 376 in the parent company and 452 in major subsidiaries[164]. - The company has established a performance evaluation mechanism for senior management, ensuring that the stock incentive plan aligns with the performance and contributions of the incentive targets[178]. - The company emphasizes a performance-based salary system, including basic salaries, performance bonuses, and project incentives for research personnel[166]. - The company has a total of 8 doctoral graduates, 44 master's graduates, and 176 bachelor's degree holders among its employees[165]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, adhering to regulations and promoting energy conservation and emission reduction in its operations[193]. - The company actively engages in social responsibility initiatives, including donations to educational institutions and organizing volunteer activities[195]. - The company has implemented measures to prevent fund misappropriation and ensure proper use of large funds[179]. - The company has signed a cooperation agreement with Huazhong Agricultural University, committing 100 million yuan for research in the animal protection industry, focusing on major disease prevention and new veterinary drug development[192].

Financial Performance - The company's revenue for Q3 2021 was CNY 210,170,120.01, representing a 0.29% increase year-over-year, while the year-to-date revenue reached CNY 745,909,515.64, up 50.27% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2021 was CNY 18,400,670.22, a decrease of 58.54% year-over-year, with a year-to-date net profit of CNY 119,728,893.47, reflecting a 23.50% increase[4] - Basic earnings per share for Q3 2021 were CNY 0.11, down 65.63% year-over-year, while the year-to-date figure was CNY 0.72, a decrease of 4.00%[5] - Total operating revenue for the third quarter reached CNY 745.91 million, a significant increase of 50.4% compared to CNY 496.38 million in the same period last year[27] - Net profit for the period was CNY 119.73 million, representing a 23.5% increase from CNY 96.94 million in the previous year[28] - The total comprehensive income for the third quarter of 2021 was CNY 119,728,893.47, compared to CNY 96,943,862.66 in the same period last year, representing a year-over-year increase of approximately 23.5%[29] Assets and Liabilities - The company's total assets as of September 30, 2021, were CNY 1,975,021,786.44, an increase of 12.72% from the end of the previous year[5] - The company’s total liabilities increased to CNY 520.48 million, up 39.5% from CNY 373.08 million at the end of 2020[26] - Total current liabilities amount to CNY 338,671,606.52, with accounts payable at CNY 79,791,915.16 and short-term loans at CNY 63,000,000.00[38] - Total non-current liabilities are CNY 34,404,111.49, including lease liabilities of CNY 6,416,560.92 and deferred income of CNY 24,702,550.57[39] - Total liabilities amount to CNY 373,075,718.01, while total equity stands at CNY 1,379,150,114.50, resulting in total liabilities and equity of CNY 1,752,225,832.51[39] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 119,590,909.85, a significant increase of 176.42% compared to the same period last year[11] - Cash inflow from operating activities reached CNY 838,964,253.89, significantly higher than CNY 447,758,161.70 in the prior year, marking an increase of approximately 87%[31] - The net cash flow from operating activities was CNY 119,590,909.85, up from CNY 43,264,235.36 in the same period last year, indicating a growth of over 176%[32] - Cash flow from investment activities showed a net outflow of CNY 50,389,141.10, compared to a larger outflow of CNY 154,705,703.12 in the previous year, reflecting an improvement in investment cash flow[33] - The company’s cash balance at the end of the period was CNY 360,261,233.85, down from CNY 907,935,759.90 at the end of the previous year[34] Inventory and Costs - The company reported a 66.42% increase in inventory, amounting to CNY 211,793,551.36, due to increased sales scale and inventory buildup[10] - The company’s gross profit margin was impacted by a 65.99% increase in operating costs, which totaled CNY 513,723,814.54 due to increased sales volume[11] - Total operating costs amounted to CNY 616.45 million, up 60.1% from CNY 384.98 million year-over-year[27] Research and Development - Research and development expenses for Q3 2021 were CNY 28,118,387.31, representing a 78.29% increase year-over-year, indicating a focus on enhancing R&D capabilities[11] - Research and development expenses rose to CNY 28.12 million, a 78.5% increase from CNY 15.77 million in the previous year[27] Shareholder Information - Wuhan Huisheng Biotechnology Co., Ltd. reported that the total number of common shareholders at the end of the reporting period was 9,612[14] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.80% of shares, totaling 82,800,000 shares[14] - The top ten shareholders include several investment firms with significant stakes, such as Shenzhen Innovation Investment Group Co., Ltd. at 5.32% and Shenzhen Hongtu Biotechnology Venture Capital Co., Ltd. at 3.70%[14] - The total number of shares held by the top ten unrestricted shareholders amounts to 118,000,000 shares[15] - The company has a total of 82,800,000 shares under lock-up due to initial public offering restrictions, set to be released on August 24, 2023[17] Future Outlook - The company anticipates a decrease in overall demand for veterinary drug products due to the livestock industry's downturn[19] - The company plans to adjust the performance assessment indicators of the stock incentive plan in response to the changing industry competition[19] - The company plans to continue expanding its market presence and investing in new product development[24] - The company is in the process of issuing convertible bonds to unspecified investors, with the application approved by the Shenzhen Stock Exchange on August 19, 2021[20] - The company has initiated the process for issuing convertible bonds, pending regulatory approval[21] Other Information - The third quarter report has not been audited, indicating that the figures may be subject to change upon final review[40] - The company has implemented new leasing standards starting in 2021, which may affect future financial reporting[40] - The report does not provide specific user data or performance guidance for future quarters[41]

Financial Performance - The company's operating revenue for the reporting period reached ¥535,739,395.63, representing an increase of 86.78% compared to the same period last year[28]. - The net profit attributable to shareholders was ¥101,328,223.25, marking a 92.77% increase year-over-year[28]. - The net cash flow from operating activities was ¥61,965,549.34, which is a significant increase of 180.99% compared to the previous year[28]. - The basic earnings per share rose to ¥0.61, reflecting a growth of 45.24% from the previous year[29]. - The total assets at the end of the reporting period amounted to ¥1,877,868,886.41, an increase of 7.17% from the end of the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥94,954,485.60, an increase of 82.60% year-over-year[28]. - The company's revenue for the reporting period reached ¥535,739,395.63, an increase of 86.78% compared to ¥286,823,409.71 in the previous year, primarily due to enhanced market expansion efforts[69]. - The gross profit margin for veterinary chemical preparations was 31.63%, with revenue increasing by 102.90% and costs rising by 130.41% compared to the previous year[72]. Sales and Revenue Growth - The company's direct sales revenue reached 316.05 million RMB, an increase of 108.76% compared to the same period last year[9]. - The sales revenue from veterinary chemical preparations was 457.66 million yuan, reflecting a year-on-year growth of 102.90%[38]. - The sales revenue from veterinary traditional Chinese medicine preparations was 15.60 million yuan, with an increase of 82.71% year-over-year[38]. - Group customers generated sales revenue of 316.05 million yuan, a growth of 108.76% compared to the previous year[40]. - Channel customers achieved sales revenue of 198.07 million yuan, marking a 59.58% increase year-over-year[40]. Product Development and Innovation - The company has obtained 142 veterinary drug approval numbers as of June 2021, indicating a strong product portfolio in the veterinary medicine sector[37]. - The company has expanded its product structure to include various veterinary medicines for pigs, poultry, aquatic animals, pets, and ruminants[37]. - The company introduced 12 high-level R&D talents, including 1 PhD and 9 master's degree holders, enhancing its innovation capabilities[41]. - The company has 25 new drug projects in progress, with 2 projects having completed submission of application materials and 6 entering clinical research[41]. - The company has developed a new generation of veterinary drugs, including the innovative drug Tylvalosin, which has received a new veterinary drug registration certificate[57]. Market Position and Strategy - The company is positioned among the top ten in the domestic veterinary chemical preparation market, with a revenue of 777 million yuan in 2020, surpassing the threshold of 429 million yuan for the top ten[59]. - The company is leveraging the trend of industry consolidation in the livestock sector to expand its market share[55]. - The implementation of new veterinary GMP standards is expected to raise industry entry barriers and enhance product quality control, benefiting leading companies like the company[54]. - The company is actively expanding into poultry, aquaculture, ruminants, and pet markets to mitigate risks associated with fluctuations in demand for swine products[103]. - The company is focused on diversifying its product offerings to reduce reliance on swine-related sales[104]. Risk Management - The company faces risks from animal epidemics, particularly African swine fever, which could significantly impact the demand for veterinary drugs[5]. - The fluctuation in raw material prices poses a risk to the company's profitability, as major veterinary raw material prices have been volatile in 2021[8]. - The company acknowledges the potential impact of downstream industry demand fluctuations on its operational performance and profitability[6]. - The company emphasizes the importance of maintaining a strong credit relationship with large-scale breeding clients to mitigate accounts receivable risks[9]. - The company has implemented strict credit approval systems to manage accounts receivable risks effectively[107]. Investment and Financial Management - The total investment during the reporting period was ¥242,565,239.63, a significant increase of 265.36% compared to ¥66,390,399.04 in the previous year[80]. - The company has utilized idle raised funds for cash management up to RMB 350 million, with all principal and returns redeemed by the end of the reporting period[87]. - The cumulative investment income from financial assets reached RMB 41.50 million by the end of the reporting period[84]. - The company plans to raise up to RMB 700 million through the issuance of convertible bonds, with the funds allocated to various projects including the expansion of production lines for antibiotics and pet formulations[158][159]. Corporate Governance and Compliance - The company has not engaged in any major litigation or arbitration matters during the reporting period, indicating a stable legal environment[135]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[130]. - The company has not reported any violations regarding external guarantees during the reporting period, reflecting sound financial practices[131]. - The company has adhered to environmental protection laws and regulations, ensuring effective treatment of major pollutants generated during production[119]. - The company has maintained a zero non-compliance rate in veterinary drug quality supervision inspections from 2012 to 2020, reflecting a strong commitment to product quality[123]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 10,018[172]. - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., has a total of 82,800,000 shares, all of which are under lock-up conditions[172]. - The company has seen a significant increase in the number of shares held by institutional investors, with notable increases from various funds[173]. - The total number of restricted shares at the end of the period is 124,210,527 shares, with 41,403,509 shares released during the reporting period[170].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 313,499,906.84, representing a 132.22% increase compared to CNY 135,002,023.52 in the same period last year[8]. - The net profit attributable to shareholders for Q1 2021 was CNY 63,457,333.99, a 150.59% increase from CNY 25,323,579.17 year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 61,542,373.26, up 145.68% from CNY 25,049,336.92 in the previous year[8]. - The basic earnings per share for Q1 2021 was CNY 0.57, an increase of 83.87% compared to CNY 0.31 in the same period last year[8]. - The total operating revenue for the first quarter of 2021 was CNY 313,499,906.84, a significant increase from CNY 135,002,023.52 in the same period last year, representing a growth of approximately 132.5%[55]. - Net profit attributable to shareholders reached CNY 63,457,333.99, reflecting a growth of 150.59% compared to the same period last year[24]. - Basic earnings per share increased to CNY 0.57, up 83.87% year-on-year[24]. - Operating profit rose to CNY 73,631,806.44, marking a 149.62% increase from the previous year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,788,363,688.87, a 2.06% increase from CNY 1,752,225,832.51 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,442,607,448.49, reflecting a 4.60% increase from CNY 1,379,150,114.50 at the end of the previous year[8]. - The total liabilities decreased to CNY 345,756,240.38 from CNY 373,075,718.01, indicating a reduction of approximately 7.3%[49]. - The company's total assets as of March 31, 2021, amounted to CNY 1,788,363,688.87, compared to CNY 1,752,225,832.51 at the end of 2020, reflecting an increase of about 2.1%[50]. - The total equity attributable to the parent company increased to CNY 1,442,607,448.49 from CNY 1,379,150,114.50, representing a growth of about 4.6%[50]. Cash Flow - The net cash flow from operating activities for Q1 2021 was negative CNY 20,061,570.80, a decrease of 277.76% compared to a positive CNY 11,285,760.37 in the same period last year[8]. - The cash and cash equivalents increased to CNY 465,240,761.42 as of March 31, 2021, compared to CNY 345,343,353.84 at the end of 2020[47]. - The cash inflow from investment activities included 410,000,000.00 from recovering investments, indicating strong investment recovery efforts[67]. - The total cash inflow from investment activities was 411,485,219.59, with a net cash flow of 152,360,259.27, a substantial improvement from -26,380,284.17 in the previous period[64]. - The cash flow from operating activities showed a total inflow of 305,652,169.46, compared to 128,494,196.22 in the prior period, indicating improved revenue generation[63]. Research and Development - Research and development expenses increased by 62.28% to CNY 5,914,988.69, indicating a focus on innovation[20]. - The company has signed three clinical contracts and is on track with its research projects, having introduced six new R&D personnel[30]. - The company obtained registration certificates for two new veterinary drugs, enhancing its market competitiveness and supporting the integration of raw material and formulation strategies[27]. Operational Challenges and Risks - The company faces risks from ongoing pandemic impacts, commodity price fluctuations, and potential credit risks from large-scale breeding group clients[31]. - The company has maintained a diversified customer base, with no significant reliance on any single customer, mitigating operational risks[28]. - The company experienced a credit impairment loss of CNY 1.68 million, compared to CNY 1.45 million in the previous year, indicating a slight increase in credit risk[56]. Investments and Projects - The company has invested a total of 85,071.25 million yuan in fundraising, with 15,293.18 million yuan utilized in the current quarter[34]. - The new automated production base project at Xingu Base has achieved a 63.01% investment progress, while the R&D and quality inspection center project has reached 69.10%[34]. - The company has completed the construction of its traditional Chinese medicine extraction workshop, which is now at the GMP acceptance stage[30]. - The company has invested CNY 26,071.25 million in the annual production project of 1,000 tons of Tylosin, with a project progress of 27.82% and expected completion by the end of 2021[37]. - The total investment for the Tylosin project is CNY 38,000 million, with CNY 7,251.73 million raised from public offerings[37]. Financial Adjustments and Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement adjustments[76]. - The first quarter report was not audited, which may affect the reliability of the financial data presented[76].

Financial Performance - The company's direct sales revenue reached RMB 432.04 million, an increase of 112.68% compared to the previous year[8]. - The company's operating revenue for 2020 was CNY 777,458,548.09, representing an increase of 81.98% compared to CNY 427,217,126.05 in 2019[21]. - The net profit attributable to shareholders for 2020 was CNY 150,156,108.11, up 118.36% from CNY 68,766,353.89 in 2019[21]. - The net profit after deducting non-recurring gains and losses was CNY 139,012,277.87, an increase of 122.12% compared to CNY 62,583,369.35 in 2019[21]. - The total assets at the end of 2020 reached CNY 1,752,225,832.51, a 169.54% increase from CNY 650,080,634.34 at the end of 2019[21]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,379,150,114.50, up 264.58% from CNY 378,281,485.59 at the end of 2019[21]. - The company achieved a basic earnings per share of CNY 1.63 in 2020, a 96.39% increase from CNY 0.83 in 2019[21]. - The net cash flow from operating activities for 2020 was CNY 48,349,261.08, a decrease of 54.06% compared to CNY 105,241,482.47 in 2019[21]. Sales and Revenue Growth - The company achieved sales revenue of 628.03 million CNY for veterinary chemical preparations, representing a year-on-year growth of 88.00%[31]. - The sales revenue for veterinary traditional Chinese medicine preparations reached 21.58 million CNY, with a year-on-year increase of 35.00%[31]. - The sales revenue for veterinary raw materials amounted to 62.59 million CNY, showing a year-on-year growth of 86.49%[31]. - The company's group clients generated sales revenue of 432.04 million CNY, reflecting a year-on-year increase of 112.68%[39]. - Revenue from veterinary raw materials and preparations accounted for ¥712,197,389.41, which is 91.61% of total revenue, showing an 85.66% increase from ¥383,598,378.09 in 2019[65]. Risk Factors - The company faces risks from animal epidemics, particularly African swine fever, which could significantly impact the demand for veterinary drugs[5]. - The fluctuation in raw material prices poses a risk to the company's profitability, as the prices of major veterinary raw materials have been on the rise since 2020[7]. - The emergence of new variants of the African swine fever virus presents challenges for vaccine development and epidemic control[5]. - The company faces risks from animal epidemics, fluctuations in downstream demand, and significant volatility in raw material prices, which could impact profitability[120][122][123]. Research and Development - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug research and development[35]. - The company has developed a new generation of broad-spectrum, high-efficiency, and low-toxicity veterinary antibiotics, which are crucial for enhancing market competitiveness[40]. - The company’s R&D efforts led to the acquisition of two invention patents related to the extraction methods of veterinary drugs, strengthening its innovation capabilities[40]. - The company has 25 new drugs under research and has obtained new veterinary drug certificates for 2 products during the reporting period[80]. - The company is focusing on the development of new veterinary drugs, with several new products for pets already certified and multiple projects under research[116]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 4.1 per 10 shares, with no bonus shares issued[8]. - The total distributable profit for the year was 217,102,201.49 yuan, with the cash dividend accounting for 100% of the profit distribution[132]. - The cash dividend for 2020 represented 30.17% of the net profit attributable to shareholders, which was 150,156,108.11 yuan[135]. - The company adheres to a profit distribution policy that prioritizes cash dividends over stock dividends[130]. - The company implemented a stable profit distribution policy, prioritizing cash dividends, with a minimum of 10% of distributable profits allocated for cash dividends over the next three years[138]. Partnerships and Market Position - The company has established stable partnerships with major domestic agricultural enterprises, including Zhengbang Technology and New Hope[30]. - The company primarily serves large-scale pig farming enterprises, making its performance highly dependent on the health of the pig farming industry[6]. - The company has established stable partnerships with major domestic agricultural enterprises, enhancing its market position[43]. - The company is actively expanding into the pet medicine market, having obtained new veterinary drug certificates for pet medications[48]. Compliance and Governance - The company maintained a zero rate of non-compliance in product quality supervision checks conducted by the Ministry of Agriculture and Rural Affairs from 2012 to 2020[30]. - The company emphasizes the importance of credit risk management, as it extends credit terms of 3-6 months to major clients[8]. - The company is committed to maintaining transparency and accountability in its operations and financial reporting[141]. - The company has not reported any non-standard audit reports for the recent period[144]. - The company has not faced any issues regarding the fulfillment of commitments made to minority shareholders[142]. Capital and Investment - The company raised a total of RMB 930.997 million through its initial public offering, with a net amount of RMB 850.7125 million after deducting issuance costs[100]. - The company is focusing on expanding its production capacity and enhancing its research and development capabilities in the pharmaceutical sector[96]. - The total investment during the reporting period was CNY 230.84 million, an increase of 87.59% compared to the previous year[93]. - The company has committed a total investment of CNY 59 million for various projects, with a cumulative investment of CNY 32.37 million, achieving a progress rate of 54.83%[103]. Employee and Social Responsibility - Employee average salary increased by 22% compared to the previous year, enhancing employee satisfaction and loyalty[63]. - The company emphasizes employee rights protection by complying with labor laws and providing social insurance benefits[174]. - The company emphasizes its commitment to social responsibility, aiming to enhance life quality through its mission[170].

武汉回盛生物科技股份有限公司 2020 年第三季度报告全文 武汉回盛生物科技股份有限公司 2020 年第三季度报告 2020-019 2020 年 10 月 1 武汉回盛生物科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张卫元、主管会计工作负责人杨凯杰及会计机构负责人(会计主 管人员)罗琼碧声明：保证季度报告中财务报表的真实、准确、完整。 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,761,311,629.39 | 650,080,634.34 | | 170.94% | | 归属于上市公司股东的净资产 | 1,329,362,397.49 | 378,281,485.59 | | 251.42% | | （元） | | | | | | | 本报告期 | 本报告期比上 ...